Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Failure 1Hepatitis C 1Hepatitis B 1Hepatic Insufficiency 1HIV Infections 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 39atezolizumab 26durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Sorafenib 7Immunoglobulin G 7regorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Raltegravir Potassium × 90 days × Clear all
NCT01022476 2026-04-06

LIVERAL

ANRS, Emerging Infectious Diseases

Phase 1/2 Completed
14 enrolled
Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, HIV Infections, Liver Failure, Hepatic Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡